{"id":"https://openalex.org/W2121476689","doi":"https://doi.org/10.2174/156720510791383831","title":"Double-Blind, Controlled Phase II Study of a 5-HT6 Receptor Antagonist, SB-742457, in Alzheimers Disease","display_name":"Double-Blind, Controlled Phase II Study of a 5-HT6 Receptor Antagonist, SB-742457, in Alzheimers Disease","alternate_titles":[],"publication_year":2010,"publication_date":"2010-05-30","ids":{"openalex":"https://openalex.org/W2121476689","doi":"https://doi.org/10.2174/156720510791383831","mag":"2121476689","pmid":"https://pubmed.ncbi.nlm.nih.gov/20043816"},"language":"en","primary_location":{"id":"doi:10.2174/156720510791383831","doi":"https://doi.org/10.2174/156720510791383831","is_oa":false,"landing_page_url":"https://doi.org/10.2174/156720510791383831","pdf_url":null,"source":{"id":"https://openalex.org/S188438558","display_name":"Current Alzheimer Research","issn_l":"1567-2050","issn":["1567-2050","1875-5828"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Alzheimer Research","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2121476689"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5027736490","display_name":"Gareth Maher\u2010Edwards","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I188950975","display_name":"GlaxoSmithKline (United Kingdom)","ror":"https://ror.org/01xsqw823","country_code":"GB","type":"company","lineage":["https://openalex.org/I188950975"]}],"countries":["GB"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"G. Maher-Edwards","raw_affiliation_strings":["GlaxoSmithKline, Uxbridge, Middlesex, UK. Gareth.C.Maher-Edwards@gsk.com","GlaxoSmithKline; Uxbridge Middlesex UK"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Uxbridge, Middlesex, UK. Gareth.C.Maher-Edwards@gsk.com","institution_ids":["https://openalex.org/I188950975"]},{"raw_affiliation_string":"GlaxoSmithKline; Uxbridge Middlesex UK","institution_ids":["https://openalex.org/I188950975"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051730849","display_name":"Marina E. Zvartau-Hind","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. Zvartau-Hind","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088485502","display_name":"Andrea J. Hunter","orcid":"https://orcid.org/0000-0002-2045-6262","observed_orcids":["https://orcid.org/0000-0002-2045-6262"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"A.J. Hunter","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":null,"display_name":"M. Gold","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. Gold","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034933236","display_name":"Gillian Hopton","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"G. Hopton","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5066824740","display_name":"Gemma Jacobs","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"G. Jacobs","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053401820","display_name":"Maria Davy","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"M. Davy","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5089633973","display_name":"Pauline M. Williams","orcid":"https://orcid.org/0000-0001-9906-6226","observed_orcids":["https://orcid.org/0000-0001-9906-6226"]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"P. Williams","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":3.7509,"has_fulltext":false,"cited_by_count":120,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.94227188,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":86,"max":99},"biblio":{"volume":"7","issue":"5","first_page":"374","last_page":"385"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.7685999870300293,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10086","display_name":"Alzheimer's disease research and treatments","score":0.7685999870300293,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10009","display_name":"Dementia and Cognitive Impairment Research","score":0.20640000700950623,"subfield":{"id":"https://openalex.org/subfields/2738","display_name":"Psychiatry and Mental health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12023","display_name":"Cholinesterase and Neurodegenerative Diseases","score":0.018699999898672104,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/5-ht6-receptor-antagonists","display_name":"5-HT6 receptor antagonists","score":0.9610000252723694},{"id":"https://openalex.org/keywords/alzheimer-s-disease","display_name":"Alzheimer's disease","score":0.949999988079071},{"id":"https://openalex.org/keywords/mild-to-moderate-dementia","display_name":"mild to moderate dementia","score":0.8460000157356262},{"id":"https://openalex.org/keywords/cognitive-impairment","display_name":"cognitive impairment","score":0.5149999856948853},{"id":"https://openalex.org/keywords/dose-response-relationship","display_name":"dose-response relationship","score":0.6959999799728394},{"id":"https://openalex.org/keywords/adas-cog","display_name":"ADAS-Cog","score":0.9940000176429749},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.5630000233650208},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.9570000171661377},{"id":"https://openalex.org/keywords/model-based-design","display_name":"model-based design","score":0.4819999933242798}],"concepts":[{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.7988929748535156},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7277035713195801},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6753770709037781},{"id":"https://openalex.org/C502032728","wikidata":"https://www.wikidata.org/wiki/Q11081","display_name":"Alzheimer's disease","level":3,"score":0.6443516612052917},{"id":"https://openalex.org/C2908647359","wikidata":"https://www.wikidata.org/wiki/Q2625603","display_name":"Population","level":2,"score":0.5329267382621765},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5234189033508301},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4876207411289215},{"id":"https://openalex.org/C44249647","wikidata":"https://www.wikidata.org/wiki/Q208498","display_name":"Confidence interval","level":2,"score":0.46863412857055664},{"id":"https://openalex.org/C204243189","wikidata":"https://www.wikidata.org/wiki/Q1363085","display_name":"Randomization","level":3,"score":0.4177534580230713},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3610432744026184},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2878270745277405},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.22273331880569458},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.08082741498947144},{"id":"https://openalex.org/C99454951","wikidata":"https://www.wikidata.org/wiki/Q932068","display_name":"Environmental health","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000544","descriptor_name":"Alzheimer Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D000544","descriptor_name":"Alzheimer Disease","qualifier_ui":"Q000523","qualifier_name":"psychology","is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011804","descriptor_name":"Quinolines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D011985","descriptor_name":"Receptors, Serotonin","qualifier_ui":"Q000502","qualifier_name":"physiology","is_major_topic":true},{"descriptor_ui":"D012702","descriptor_name":"Serotonin Antagonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D013450","descriptor_name":"Sulfones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D016037","descriptor_name":"Single-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.2174/156720510791383831","doi":"https://doi.org/10.2174/156720510791383831","is_oa":false,"landing_page_url":"https://doi.org/10.2174/156720510791383831","pdf_url":null,"source":{"id":"https://openalex.org/S188438558","display_name":"Current Alzheimer Research","issn_l":"1567-2050","issn":["1567-2050","1875-5828"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-d","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320079","host_organization_name":"Bentham Science Publishers","host_organization_lineage":["https://openalex.org/P4310320079"],"host_organization_lineage_names":["Bentham Science Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Alzheimer Research","raw_type":"journal-article"},{"id":"pmid:20043816","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/20043816","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Current Alzheimer research","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320337359","display_name":"National Institute of Neurological Disorders and Stroke","ror":"https://ror.org/01s5ya894"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2125563559","https://openalex.org/W2068669123","https://openalex.org/W4243062371","https://openalex.org/W2150645876","https://openalex.org/W2048061133","https://openalex.org/W1604099394","https://openalex.org/W2006552935","https://openalex.org/W1989525227","https://openalex.org/W1999018607","https://openalex.org/W2800293813"],"abstract_inverted_index":{"BACKGROUND:":[0],"This":[1],"randomized,":[2],"double-blind,":[3],"placebo-controlled":[4],"study":[5],"investigated":[6],"the":[7,12,70,97,136,228],"efficacy":[8,67],"and":[9,46,81,118,247,250],"tolerability":[10],"of":[11,35,74,156],"5-HT6":[13],"receptor":[14],"antagonist,":[15],"SB-742457,":[16],"in":[17,85,96,112,176,225,227,254],"subjects":[18,27,132],"with":[19,76,128,152],"mild-to-moderate":[20],"probable":[21],"Alzheimer's":[22,86],"disease":[23],"(AD).":[24],"METHODS:":[25],"Participating":[26],"had":[28],"a":[29,40,109,147,153],"Mini-Mental":[30],"State":[31],"Examination":[32],"(MMSE)":[33],"score":[34,80,92],"12":[36],"to":[37,50,107,123],"26":[38],"after":[39],"4-week,":[41],"single-blind,":[42],"placebo":[43,194],"run-in":[44],"phase,":[45],"were":[47,69,133],"randomized":[48],"(2:1:1:2)":[49],"receive":[51],"placebo,":[52],"SB-742457":[53,125,199,229,237,243],"5":[54],"mg,":[55,57],"15":[56],"or":[58,120],"35":[59,126,200],"mg":[60,127,201],"once":[61],"daily":[62],"for":[63,150,172,198,233,240],"24":[64,145,197],"weeks.":[65],"Coprimary":[66],"endpoints":[68],"Clinician's":[71],"Interview-Based":[72],"Impression":[73],"Change":[75],"caregiver":[77],"input":[78],"(CIBIC+)":[79],"change":[82,173],"from":[83,174,193],"baseline":[84,175],"Disease":[87],"Assessment":[88],"Scale-Cognitive":[89],"subscale":[90],"(ADAS-Cog)":[91],"at":[93,143,195],"Week":[94,144,196],"24,":[95],"intent-to-treat":[98],"(ITT)":[99],"population.":[100],"A":[101],"model-based":[102],"design":[103],"provided":[104],"90%":[105],"power":[106,122],"detect":[108],"linear":[110,140],"trend":[111,141],"treatment":[113,191],"response":[114,149,170],"across":[115],"increasing":[116],"doses":[117],">":[119],"=90%":[121],"compare":[124],"placebo.":[129,241],"RESULTS:":[130],"371":[131],"randomized.":[134],"In":[135],"ITT":[137],"population":[138],"(n=357),":[139],"analysis":[142],"suggested":[146],"dose":[148,159,169,181],"CIBIC+":[151,206],"mean":[154,190],"slope":[155,171],"-0.05":[157],"points/5-mg":[158,180],"increase":[160,182],"(95%":[161,183,207],"confidence":[162],"interval":[163],"[CI]:":[164],"-0.09,":[165],"-0.01;":[166],"p=0.016).":[167],"The":[168,188],"ADAS-Cog":[177,215],"was":[178,203,244],"-0.22":[179],"CI:":[184,208,218],"-0.45,":[185],"0.01;":[186],"p=0.059).":[187],"adjusted":[189],"difference":[192],"(-0.31)":[202],"significant":[204],"on":[205,214],"-0.62,":[209],"-0.00;":[210],"p=0.047)":[211],"but":[212],"non-significant":[213],"(-1.28":[216],"[95%":[217],"-2.96,":[219],"0.40];":[220],"p=0.135).":[221],"Adverse":[222],"events":[223],"occurred":[224],"24-37%":[226],"groups":[230],"vs":[231,238],"29%":[232],"placebo;":[234],"11-16%":[235],"discontinued":[236],"15%":[239],"COMMENTS:":[242],"generally":[245],"safe":[246],"well":[248],"tolerated":[249],"may":[251],"be":[252],"efficacious":[253],"AD.":[255]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2121476689","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":1},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":12},{"year":2020,"cited_by_count":7},{"year":2019,"cited_by_count":5},{"year":2018,"cited_by_count":10},{"year":2017,"cited_by_count":7},{"year":2016,"cited_by_count":9},{"year":2015,"cited_by_count":8},{"year":2014,"cited_by_count":13},{"year":2013,"cited_by_count":9},{"year":2012,"cited_by_count":13}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
